Location History:
- Melrose, MA (US) (2010)
- Guilford, CT (US) (2022)
Company Filing History:
2 out of 5,463 
1 out of 1,327 
1 out of 1 Years Active: 2010-2022
Title: Christos Hatzis: Innovator in Cancer Therapy
Introduction
Christos Hatzis is a notable inventor based in Melrose, MA (US). He has made significant contributions to the field of cancer therapy, particularly in understanding hormonal sensitivity in tumors. With a total of 2 patents, Hatzis has developed innovative methods that aim to improve patient outcomes in breast cancer treatment.
Latest Patents
Hatzis's latest patents include groundbreaking methods for assessing tumor sensitivity to hormonal therapy. The first patent, titled "Targeted measure of transcriptional activity related to hormone receptors," introduces a sensitivity index for endocrine therapy based on estrogen and progesterone receptor-related genes. This method not only helps in determining the effectiveness of hormonal treatments but also provides a framework for treating breast cancer patients identified as sensitive to endocrine therapy.
The second patent, "Method of measuring residual cancer and predicting patient survival," outlines a novel approach for evaluating a patient's residual cancer burden. This method utilizes various metrics, including the dimensions of the primary tumor and the status of regional lymph nodes, to predict survival and relapse rates in patients undergoing tumor therapy.
Career Highlights
Throughout his career, Christos Hatzis has worked with prestigious institutions, including the University of Texas System and Yale University. His work has been instrumental in advancing the understanding of cancer treatment methodologies and improving therapeutic strategies.
Collaborations
Hatzis has collaborated with esteemed colleagues such as William Fraser Symmans and Bruno Sinn. These partnerships have further enriched his research and contributed to the development of his innovative patents.
Conclusion
Christos Hatzis stands out as a significant figure in the realm of cancer therapy innovation. His patents reflect a commitment to enhancing treatment strategies and improving patient care in oncology.